Introduction: Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity (T 50 ) is a novel functional test, which is associated with all-cause mortality in CKD and measures the ability of serum to delay the formation of crystalline nanoparticles. Theoretically, increasing serum Mg should improve T 50 and thereby reduce the propensity towards ectopic calcification.
C hronic kidney disease (CKD) affects approximately 13% of the general population 1 and is associated with increased risk of cardiovascular disease (CVD) because of both traditional and nontraditional CVD risk factors. 2 Among the nontraditional CVD risk factors, disturbances in mineral and bone disease are associated with vascular calcification, 3 which is associated with increased cardiovascular mortality in end-stage renal disease. 4 Key factors in this regard are phosphate (PO 4 ) and calcium (Ca), which can precipitate and induce an osteogenic transformation in the vascular smooth muscle cells of the arteries causing them to calcify and stiffen.
Epidemiological studies have found associations between higher levels of serum magnesium (Mg) and improved survival among patients suffering from CKD 5 and end-stage renal disease, [6] [7] [8] [9] [10] [11] [12] [13] and higher levels of serum Mg ( s Mg) are associated with reduced progression of CKD. 5, 14 These associations are thought to be mediated by an antagonistic effect of Mg on the procalcifying milieu in CKD. 15 In vitro calcifications induced by Ca and high concentrations of PO 4 can be prevented or reversed by adding or increasing Mg, which appears to be mediated by both upregulation of factors that inhibit calcification and downregulation of factors that promote calcification. [16] [17] [18] [19] [20] Also, 2 small clinical trials of Mg supplementation in end-stage renal disease have shown reduced progression of vascular calcification. 21, 22 Thus, Mg supplementation could potentially be a therapeutic option to attenuate the progression of vascular calcification in CKD. Because studies have shown that influx of Mg into the vascular smooth muscle cell is important for prevention of vascular calcification, 16, 18, 19 measurement of any effect of Mg therapy on intracellular Mg ( i Mg) would be of interest. However, because of the renal excretion of Mg, there is a risk that Mg therapy might result in toxic hypermagnesemia in patients with reduced kidney function. So far, no studies have examined the effect of oral Mg supplementation on i Mg in subjects with CKD stages 3 and 4, or the safety of this intervention.
Serum calcification propensity (T 50 ) is a novel functional test, which determines the ability of serum to resist Ca/PO 4 precipitation by measuring the timepoint of conversion from primary to secondary calciprotein particle. 23 Previous studies have shown that low T 50 predicts all-cause mortality in CKD stages 3 and 4 24 and kidney transplant recipients, 25, 26 as well as graft failure in kidney transplant recipients. 25 T 50 is believed to reflect the propensity towards ectopic calcification, although so far low T 50 has not been directly associated with progression of vascular calcification. In vitro data indicate that Mg improves T 50 , 23 but so far this has not been examined in a clinical trial.
We conducted a randomized placebo-controlled double-blinded clinical trial to investigate the efficacy and safety of 2 different doses of oral Mg supplementation on i Mg in subjects with CKD stages 3 and 4, as well as any effects on T 50 . We hypothesized that greater doses of Mg supplementation would result in a greater increase in i Mg compared with placebo as well as improving T 50 in subjects with CKD stages 3 and 4 and low or low-normal s Mg.
METHODS

Subjects
Subjects were recruited between October 2014 and February 2015 from the outpatient clinic at the Division of Nephrology, Roskilde County Hospital, Denmark. All patients were screened before planned visits to the clinic and those matching trial criteria were offered participation in the trial. Inclusion criteria were age > 18 years, estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m 2 , total s Mg < 0.82 mmol/l, safe contraceptive treatment in women of childbearing age, and written informed consent. Exclusion criteria were current treatment with hemodialysis or peritoneal dialysis, kidney transplant recipient, treatment with Mgcontaining medication or supplements, parathyroid hormone (PTH) > 66 rmol/l, cancer, other medical condition that in the opinion of the investigators would prohibit participation in the trial, pregnancy or breastfeeding, allergies to any contents of the study medication, and participation in other interventional trials.
Design
The trial was an investigator-initiated double-blinded placebo-controlled clinical trial in which subjects were randomized in a ratio of 1:1:1 to 8 weeks of oral treatment with either placebo twice daily, slowrelease Mg hydroxide 360 mg (equivalent to 15 mmol of elemental Mg) (Mablet, Gunnar Kjems ApS, Copenhagen, Denmark) once daily and placebo once daily, or slow-release Mg hydroxide 360 mg twice daily. Mg hydroxide and placebo tablets were identical in appearance, constituents, and containers, and did not contain Ca. Study medication was packed in consecutively numbered containers according to a computer generated block-randomized randomization list, and was administered to subjects consecutively as they entered the trial. Subjects and investigators were blinded to the study medication during the course of the trial.
At weeks 0, 4, and 8, sublingual epithelial cells were sampled for i Mg and nonfasting blood samples, 24-hour urine samples were collected, and an electrocardiogram was performed. Subjects were instructed to maintain their usual diets and not to begin treatment with Mgcontaining medication or supplements for the duration of the trial. Adherence was assessed by pill count at week 8.
The primary endpoint was a change in i Mg as assessed by energy dispersive X-ray microanalysis of sublingual epithelial cells, 27 as this has been shown previously to correlate with i Mg in human atrial cardiomyocytes. 28 Based on previous studies, [29] [30] [31] [32] [33] an increase in i Mg of 2.0 mEq/l with a SD of 2.0 mEq/l was considered clinically relevant. With a probability of type 1 error (a) of 5% and power of 80% (1 À b) a sample size of 10 subjects per group would be necessary to detect a difference of 2.0 mEq/l. A dropout rate of 15% was anticipated, and therefore 36 subjects in total were included in the trial (12 subjects per group). Dropouts were not replaced. Secondary endpoints were blood levels of total Mg, PO 4 Blood samples were drawn from subjects in nonfasting states. Samples for measurement of T 50 , fetuin-A, and FGF23 were collected and immediately stored at -80 C. The analyses were performed in bulk in the same analytical run so as to eliminate interassay variation. Blood levels of total Mg, ionized Ca, PO 4 , PTH, 25-OH-D 3 , creatinine, hemoglobin, bicarbonate, and albumin were measured on a routine basis by the same standardized methods at the local department of clinical biochemistry. Urine samples were collected over 24 hours in 2.5-liter containers, which contained 100 ml of 2.5% hydrochloric acid. u Mg and u PO 4 were analyzed on a routine basis by the same standardized analysis at the local laboratory.
T 50 was measured using a standardized method previously described. 23 FGF23 was measured using the human intact FGF23 ELISA kit 60-6500 (Immutopics, San Clemente, CA), and fetuin-A was measured using the human intact Quantikine human Fetuin A ELISA kit DFTA00 (R&D Systems, Minneapolis, MN). PTH was measured using the second-generation intact PTH immunoassay (reference values 1.5-7.6 rmol/l) (ADVIA Centaur, Siemens, Erlangen, Germany). eGFR was calculated using the CKD-EPI formula.
Statistical Analysis
The biostatistical evaluation was performed blinded using SPSS version 22.0.0.0 (IBM Corporation, Armonk, NY). Continuous data were described as mean AE SD for data of a normal distribution, and as median and interquartile range (25th-75th percentile) for data of a non-normal distribution. For assessment of within-group changes, a one-way analysis of variance with repeated measures or a Friedman test (both with post hoc Bonferroni correction for multiple measures) was applied for data with Normal or non-Normal distributions, respectively. For assessment of between-group changes of i Mg, s Mg, u Mg, and T 50 , a mixed 2-way analysis of variance with repeated measures was applied. All tests were 2-sided tests and a P < 0.05 was considered statistically significant.
RESULTS
Ninety-two subjects met inclusion criteria for the trial, and of these, 36 agreed to participate ( Figure 1 ). Demographic characteristics of trial subjects are displayed in Table 1 . According to tablet count at final follow-up visit compliance >95% was achieved in all subjects. (Table 3) , but there was a significant effect of time and intervention on both s Mg and u Mg (Table 3) .
T 50 increased significantly in the Mg 30 mmol/d group compared with baseline at both weeks 4 and 8, while only increasing significantly within the Mg 15 mmol/d group compared with baseline at week 4, and with no significant changes within the placebo group (Table 4 and Figure 3 ). There was also a significant effect of time, and intervention on T 50 and post hoc tests revealed that Mg 30 mmol/d produced significantly greater changes to T 50 over time compared with placebo or Mg 15 mmol/d (Table 3) . Factors other than Mg known to affect T 50 (fetuin-A, PO 4 , ionized Ca, albumin, bicarbonate) did not change significantly in either group throughout the trial (Table 4) . eGFR did not change significantly throughout the trial, and there were no changes in blood analyses of mineral metabolism or u PO 4 in any of the treatment groups (Table 5 ). There was a significant effect of time on change medication similar to previously experience from other medications (abdominal cramps, flushing, and palpitations), and intolerance to one of the tablet constituents was suspected (most likely talcum). There were 2 cases of community-acquired pneumonia in the placebo group that required hospital admissions, and one case of asthma exacerbation in the Mg 15 mmol/d group that required treatment with corticosteroids. None of the adverse events were considered to be due to the effects of Mg. Incidence of loosening of stool was identical (2 in each treatment group), but none of the study participants experienced frank diarrhea. Reported as mean AE SD or median and interquartile range for weeks 0, 4, and 8 (as relevant), and change with 95% confidence interval or absolute change for differences between time points (as relevant). ANOVA, analysis of variance; CI, confidence interval; ion Ca, ionized calcium; HCO 3 , bicarbonate; Mg, magnesium; s PO 4 , serum phosphate; T 50 , serum calcification propensity. *P < 0.05. **P < 0.05 after Bonferroni adjustment for multiple comparisons.
None of the adverse events were attributed to Mg supplementation.
DISCUSSION
The main finding of this clinical trial is that oral Mg supplementation using slow-release Mg hydroxide 30 mmol/d does not affect i Mg as assessed by energy dispersive X-ray microanalysis after 8 weeks of treatment, despite significant increases in s Mg and u Mg. Furthermore, this trial has shown for the first time that calcification propensity T 50 can be improved by oral Mg supplementation in CKD stages 3 and 4. Study participants were included based on low to low-normal levels of s Mg, and it is plausible that subjects may have been Mg-depleted based on the low i Mg and u Mg in all groups at baseline. Thus, Mg supplementation would first have to replenish total body Mg stores before "spilling over" into the serum, which could explain the relatively modest increase in s Mg and u Mg. We speculate that i Mg stores increased in other compartments of the body (e.g., bone or muscle), and only later in epithelial cells from the sublingual mucosa, which would account for the lack of a treatment effect on i Mg. 23 The final measurement of T 50 in the group treated with Mg 30 mmol/d was similar to that of healthy adults without CKD, 34 and the intervention shifted the mean T 50 about half a SD for patients with predialysis CKD, which according to previous data might lead to a 20% risk reduction in all-cause mortality. 24 Mg delays the formation of secondary calciprotein particles in the T 50 test. 23 A recent in vitro study convincingly demonstrated that secondary (but not primary) calciprotein particles induce calcification of vascular smooth muscle cells, 35 suggesting that delaying the time until formation of secondary calciprotein particles (i.e., increasing T 50 ) might improve calcification propensity via this mechanism. Thus, T 50 appears to be a modifiable risk factor and might be useful not only for risk assessment, but also for monitoring and guiding therapy directed at inhibition of Ca/PO 4 crystal formation. Whether the improvement of T 50 observed in this trial is sustained over a longer treatment period, and whether this translates to a reduction in clinically relevant outcomes (e.g., cardiovascular events or all-cause mortality) will have to be studied in a future randomized clinical trial, which may use individualized and combined interventions aimed at improving T 50 .
Mg supplementation might be expected to lower s PO 4 in the same manner as Mg-containing PO 4 binders. We found no significant differences in s PO 4 , u PO 4 or intact FGF23 in any of the groups, suggesting that Mg supplementation with the formulation used in this trial does not affect PO 4 homeostasis in any clinically meaningful way. However, the sample size and increases in s Mg were probably not powered to definitively rule out any interaction and larger study populations would be needed to answer this question. Mg supplementation has previously been a concern in CKD and end-stage renal disease because of the risk of hypermagnesemia due to impaired renal excretion of Mg. There is general consensus that hypermagnesemia is likely not symptomatic at s Mg < 2.0 mmol/l 36 and that serious complications only occur at s Mg > 3.0 mmol/l. Based on this trial, 8 weeks of Mg supplementation with slow-release Mg hydroxide is safe at doses up to 30 mmol/d in subjects with low or low-normal s Mg and eGFR down to 15 ml/min per 1.73 m 2 (the lowest eGFR of any subject in this trial). However, whether there are risks associated with longer treatment duration or in subjects with higher levels of s Mg was not assessed in this trial.
There are limitations and strengths to the current trial. Limitations include that energy dispersive X-ray microanalysis of sublingual epithelial cells was used as a proxy for i Mg, and not bone, vascular, or muscle biopsy, which are the gold standards for measurement of Mg levels in these tissues. Also, the method has not previously been applied to patients with CKD, which might have confounded the results. Furthermore, the sample size was small and the trial was of a short duration. Lastly, the formulation of slow-release Mg hydroxide used in this trial was chosen because it is widely used and readily available in Denmark. It is possible that other Mg formulations with greater bioavailability would have produced different effects on measures of Mg and on T 50 . Strengths of the trial include its single-center, randomized controlled and blinded study design.
In conclusion, 8 weeks of Mg supplementation using slow-release Mg hydroxide 30 mmol/d did not affect i Mg in sublingual epithelial cells. Mg supplementation improved T 50 , which might aid in treating systemic calcification propensity. Mg supplementation was safe and well tolerated with no adverse events related to Mg treatment and no incidences of symptomatic hypermagnesemia. Slow-release Mg hydroxide 30 mmol/d might therefore be useful for increasing s Mg in future clinical trials addressing vascular calcification or calcification propensity in CKD stages 3 and 4.
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